Literature DB >> 11238791

Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia.

S A Atkinson1.   

Abstract

Extremely low birth weight infants who develop severe respiratory disease may have special nutrient requirements imposed by a combination of enhanced utilization of nutrients or the need for epithelial cell repair resulting from the disease process, as well as to support catch-up growth. Inositol, free fatty acids, vitamin E and vitamin A are proposed as nutrients for which infants at risk of chronic pulmonary insufficiency may have special requirements. Of these nutrients, only for vitamin A does suggestive evidence exist that high doses when given intramuscularly may reduce the incidence of death or chronic lung disease. Exogenous steroid therapy (dexamethasone), which is often used to improve pulmonary compliance in ventilated premature infants, may compromise vitamin A status and induce restricted somatic and bone mineral growth. Supplemental nutrition by means of enriched infant formulas has provided benefits in growth and bone mass accretion to infants recovering from bronchopulmonary dysplasia up to 3-mo corrected age. This growth advantage was not sustained over the subsequent 9 mo, suggesting that prolonged nutritional support is required until catch-up growth is complete. Further studies are required to delineate the needs for specific nutrients such as antioxidant vitamins and minerals or vitamin A that may play a role in preventing severe chronic lung disease in premature infants. As well, the role of supplemental nutrition (beyond the requirements of term infants) to support catch-up growth and maintenance during the critical stages of early development requires further investigation before evidence-based nutrient recommendations can be developed for this special population of infants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238791     DOI: 10.1093/jn/131.3.942S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  12 in total

Review 1.  Mitochondrial bioenergetics and pulmonary dysfunction: Current progress and future directions.

Authors:  Vadim S Ten; Veniamin Ratner
Journal:  Paediatr Respir Rev       Date:  2019-04-12       Impact factor: 2.726

2.  Comparison of two types of TPN prescription methods in preterm neonates.

Authors:  Maria Skouroliakou; Katerina Koutri; Maria Stathopoulou; Ekaterini Vourvouhaki; Ifigenia Giannopoulou; Antonios Gounaris
Journal:  Pharm World Sci       Date:  2009-01-24

3.  Enteral zinc supplementation and growth in extremely-low-birth-weight infants with chronic lung disease.

Authors:  Ala K Shaikhkhalil; Jennifer Curtiss; Teresa D Puthoff; Christina J Valentine
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-02       Impact factor: 2.839

4.  Growth in post-viral chronic lung disease.

Authors:  Mariana del Pino; Gabriela Bauer; Hebe González Pena; Mario Grenoville; Horacio Lejarraga
Journal:  Eur J Pediatr       Date:  2006-06-15       Impact factor: 3.183

5.  The components of VARA, a nutrient-metabolite combination of vitamin A and retinoic acid, act efficiently together and separately to increase retinyl esters in the lungs of neonatal rats.

Authors:  A Catharine Ross; Nan-qian Li; Lili Wu
Journal:  J Nutr       Date:  2006-11       Impact factor: 4.798

6.  Vitamin A and beta-carotene supply of women with gemini or short birth intervals: a pilot study.

Authors:  Christiane Schulz; Ulrike Engel; Rolf Kreienberg; Hans Konrad Biesalski
Journal:  Eur J Nutr       Date:  2006-11-10       Impact factor: 5.614

7.  Arginyl-glutamine dipeptide or docosahexaenoic acid attenuates hyperoxia-induced small intestinal injury in neonatal mice.

Authors:  Nan Li; Liya Ma; Xueyan Liu; Lynn Shaw; Sergio Li Calzi; Maria B Grant; Josef Neu
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-04       Impact factor: 2.839

Review 8.  Current perspectives on the prevention and management of chronic lung disease in preterm infants.

Authors:  Prakesh S Shah
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies.

Authors:  Carl T D'Angio; William M Maniscalco
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Randomized controlled trial of docosahexaenoic acid supplementation in midwestern U.S. human milk donors.

Authors:  Christina J Valentine; Georgia Morrow; Michael Pennell; Ardythe L Morrow; Amanda Hodge; Annette Haban-Bartz; Kristin Collins; Lynette K Rogers
Journal:  Breastfeed Med       Date:  2012-05-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.